Skip to main content
Midas Edge

Marker Therapeutics, Inc.

For the period ended Dec 31, 2024. Filed Mar 31, 2025.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2024 · Filed Mar 31, 2025

MRKR$0.95-4.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Equity

​​​​​​​​​​​​​​​
​ · ​ · ​ · ​ · ​ · Additional · ​ · ​ · Total
​ · ​ · Common Stock · ​ · Paid- · ​ · Accumulated · ​ · Stockholders’
​ · Shares · Par value · in Capital · Deficit · Equity
Balance at January 1, 20238,405,771​​8,406​​447,641,680​​(428,049,049)​​19,601,037
Shares issued pursuant to ATM and Lincoln Park agreements​277,834​​277​​1,014,363​​—​​1,014,640
Issuance of common stock as commitment fee​180,410​​180​​(180)​​—​​—
Issuance of common stock from exercise of stock options​27,518​​28​​90,450​​—​​90,478
Stock-based compensation—​—​1,583,202​—​1,583,202
Net loss—​—​—​(8,236,814)​(8,236,814)
Fractional shares adjustment due to reverse split​(113)​​—​​—​​—​​—
Balance at December 31, 20238,891,420​​8,891​​450,329,515​​(436,285,863)​​14,052,543
Shares purchased pursuant to ATM agreement​8,178​​8​​36,894​​—​​36,902
Issuance of common stock from exercise of stock options25,602​​25​​62,134​​—​​62,159
Issuance of common stock, prefunded warrants and warrants for cash, net of offering costs of $1.2 million​1,783,805​​1,784​​14,890,469​​—​​14,892,253
Stock-based compensation—​​—​​245,864​​—​​245,864
Net loss—​​—​​—​​(10,731,315)​​(10,731,315)
Balance at December 31, 202410,709,005​​10,708​​465,564,876​​(447,017,178)​​18,558,406
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.